1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The intent of the FY21 PRARP ADRA is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice. The FY21 PRARP ADRA mechanism defines biomarker qualification as the evidentiary process of linking a biomarker with biological processes and clinical endpoints. Applications may consider elements of biomarker validation as part of the application. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Applications that detail biomarker validation work should demonstrate how this research is relevant to overall biomarker qualification. As part of the application, the proposed biomarkers should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of AD/ADRD as the study endpoint. The FY21 PRARP ADRA does not support basic discovery of biomarkers. As such, animal research is prohibited. The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to military risk factor-related research and AD/ADRD. As part of the application, the Principal Investigator (PI) should demonstrate that the study team has experience in both military risk factor-related research and AD/ADRD.The FY21 PRARP ADRA encourages applications to consider fluid-based, imaging-based, retinal, or wearable devices as potential diagnostics. Applications must provide a plan that demonstrates access to a suitable cohort and a plan for participant accrual. Suitable cohorts must be relevant to the military risk factor identified as part of the application. Due to nature of the FY21 PRARP ADRA, studies are required to prospectively recruit study participants. Applications must therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. FY21 PRARP ADRA applications must be impact-based.
Funding Opportunity Number: W81XWH-21-PRARP-ADRA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $15M total program funding.
Get alerted about grants like this
Get emailed when new opportunities from “Dept. of the Army -- USAMRAA” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $15M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was July 21, 2021, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Yes — DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award is offered by Dept. of the Army -- USAMRAA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
To increase research capacity for NF, the NFRP is offering the NFRA. The intent of the NFRA is to provide a framework of intensive mentoring and iterative guidance with proposed research, national networking, collaborations, and a peer group of junior faculty (Scholars). The NFRP NFRA will bring together established NF investigators (one Director and one Deputy Director) and early-career independent investigators (Scholars) and their Career Guides to develop successful, highly productive NF scientists and clinicians that will conduct research with the aim of lessening the clinical impact of NF1, NF2, and schwannomatosis. The NFRA is a multi-institutional interactive virtual academy platform designed to offer support to NFRA Scholars with the goal to advance innovative, high impact NF research through a collaborative and career development environment.The functioning NFRA will consist of Scholars and their Career Guides (mentors) from different institutions, and an Academy Director and Deputy Director (see Figure 1 below). The Academy Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with their Career Guides, assess the progress of the Scholars, and facilitate communication and collaboration among all Academy members. The Career Guide is not required to be at the same institution as the Scholar; however, if the (primary) Career Guide is from a different institution, a secondary Career Guide at the Scholar’s institution is needed. The NFRA will afford Scholars opportunities to operate in a collegial, highly dynamic, and cutting-edge center to move early-career investigators towards positions as leaders in NF conducting impactful research.During this first phase of the academy, the NFRP is offering the FY24 NFRALA funding opportunity to solicit applications for an Academy Director and Deputy Director to lead the NFRA. The Academy Director and Deputy Director (referred to as Academy Leadership) must be established NF researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early-career independent investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars in the NFRA. An objective of the NFRA leadership team is to establish the Academy structure in its first year and in subsequent years, conduct oversight of this activity. Other objectives will include execution of research that will engage NFRA FY25 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in NF disorders. The leadership team will identify and offer opportunities to network with other NFRP FY25 Early Investigator Research Award recipients (and subsequent year awardees) and NFRP FY25 New Investigator Award – Early-Stage Investigator (NIA – ESI) Award recipients (and subsequent year awardees). In the second stage of the academy, the NFRP anticipates release of funding opportunities for the Scholars who will conduct their research under the guidance of the NFRA leadership team. Funding Opportunity Number: HT942524NFRPNFRALA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $1.5M total program funding.
Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Concept Award supports highly innovative, untested, potentially groundbreaking concepts, theories, paradigms and/or basic kidney cancer research. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation in kidney cancer. Applications must describe how the new concept will be innovative and present a novel course of investigation in the field of kidney cancer. Distinctive Features: • Preliminary data are not allowed. • This is a blinded funding mechanism. Applications to this funding opportunity will undergo a double-blinded peer review. Applications must not include any materials that may identify the Principal Investigator (PI), a collaborator, or the organization of the PI or collaborator. • Due to the blinded nature of the review process, identifying or making references to the PI, collaborator(s), or their organization(s) in the proposal (Project Narrative, List of Abbreviations, Acronyms, Symbols, Statement of Work, Impact Statement and Innovation Statement) is prohibited and will result in administrative rejection of the application. Funding Opportunity Number: HT942526KCRPCA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $840K total program funding.
The FY2026 Department of Defense Multidisciplinary University Research Initiative (MURI) program supports basic research in science and engineering at U.S. institutions of higher education, with emphasis on multidisciplinary research where more than one traditional discipline interacts. The Army, Navy, and Air Force basic research offices are seeking applications across 22 topic areas including artificial intelligence and autonomy, information sensing and processing, and systems manipulation. MURI grants typically provide $1.25 million to $1.5 million per year for three years with option to extend two additional years. Approximately $170 million in total funding is available annually across all topics. The program is administered through the Office of Naval Research (ONR), Army Research Office (ARO), and Air Force Office of Scientific Research (AFOSR).
The NSF Convergence Accelerator is a grant from the National Science Foundation (NSF) that funds multidisciplinary teams working to solve national-scale societal challenges through convergence research and innovation. Launched in 2019 under NSF's Directorate for Technology, Innovation and Partnerships, the program operates in two phases: Phase 1 awards are up to $750,000, with successful teams advancing to larger Phase 2 awards. Eligible applicants include institutions of higher education and nonprofit or for-profit organizations. Track I and Track K focus on specific high-priority topics announced each funding cycle. The next deadline is June 15, 2026. Proposals must comply with updated NSF research security policies effective July 2025.
AFWERX is the innovation arm of the Department of the Air Force powered by the Air Force Research Laboratory (AFRL), comprising four core arms: AFVentures, Spark, Prime, and SpaceWERX. The 2026 SBIR/STTR program supports U.S.-owned small businesses developing AI, autonomous systems, and dual-use technologies aligned with the Department of the Air Force's strategic goal of becoming an AI-first force. AFWERX uses a predictable monthly cadence with pre-releases on the first Wednesday of each month, followed by one-month open submission windows. The program offers a structured progression from Phase I feasibility studies ($75K-$180K) through Phase II prototype development ($1.25M-$1.8M) to growth-stage funding via TACFI ($375K-$2M) and STRATFI ($3M-$15M), enabling small AI companies to scale from initial concept to operational deployment. AI focus areas align with the DAF AI Strategy released in 2026, including decision-support AI, autonomous platforms, AI for predictive maintenance, computer vision for ISR, and human-machine teaming. Upcoming FY2026 open solicitations include DoW SBIR Specific Topic 26.BZ Release 1 (May 6-June 3, 2026), Release 2 (May 27-June 24, 2026), and STTR Specific Topic 26.TZ Release 1 (May 6-June 3, 2026).